2 results match your criteria: "Department of Pathology. 200032. Shanghai. China. Electronic address: ji.yuan@zs.hospital.sh.cn.[Affiliation]"
Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.
Ann Diagn Pathol
February 2024
Zhongshan Hospital Fudan University, Department of Pathology. 200032. Shanghai. China. Electronic address:
Article Synopsis
- Immune checkpoint inhibitors (ICIs) paired with anti-angiogenic drugs can have effective anti-cancer effects, but they may also lead to immune-mediated hepatitis (IMH).
- A study analyzed 100 IMH patients to compare the severity of liver injury between those treated with ICIs alone and those treated with a combination of ICIs and anti-angiogenic therapy.
- The results indicated no significant increase in overall liver injury severity with the combination therapy; however, certain types of liver inflammation were more pronounced in the combination group, while treatment outcomes remained similar between both groups.
Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
J Hepatol
March 2018
State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; University of Chinese Academy of Sciences, 320 Yueyang Road, Shanghai 200031, China; School of Life Science and Technology, ShanghaiTech University, 100 Haike Road, Shanghai 201210, China. Electronic address:
Background & Aims: AT-rich interaction domain 1a (Arid1a), a component of the chromatin remodeling complex, has emerged as a tumor suppressor gene. It is frequently mutated in hepatocellular carcinoma (HCC). However, it remains unknown how Arid1a suppresses HCC development and whether Arid1a deficiency could be exploited for therapy, we aimed to explore these questions.
View Article and Find Full Text PDF